Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate.
Rosell
R
R
Spanish Lung Cancer Group, Medical Oncology Unit, Germans Trias i Pujol University Hospital, Badalona, Spain.
Gómez-Codina
J
J
Anton
A
A
Sánchez
J J
JJ
Vadell
C
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
D015251:Epirubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D002945:Cisplatin